Introduction {#s1}
============

Centrioles are microtubule-based structures that recruit a surrounding pericentriolar material (PCM) to form the centrosome ([@bib58]; [@bib23]). Centrosomes nucleate the formation of the microtubule cytoskeleton in interphase cells and form the poles of the mitotic spindle during cell division. In quiescent cells, centrioles dock at the plasma membrane and act as basal bodies that template the formation of cilia and flagella ([@bib6]). Cycling cells tightly couple centriole biogenesis with cell cycle progression. Centriole duplication begins at the G1-S phase transition when a new procentriole grows perpendicularly from a single site at the proximal end of each of the two parent centrioles. In late G2 phase, the two centriole pairs separate and increase PCM recruitment to promote the formation of the mitotic spindle. At the end of mitosis, the centrosomes are equally partitioned so that each daughter cell inherits a pair of centrioles. Defects in centriole biogenesis can result in the formation of supernumerary centrosomes which promote mitotic errors that can contribute to tumorigenesis ([@bib49]; [@bib50]; [@bib2]; [@bib68]; [@bib11]). Moreover, mutations in centriole proteins are linked to growth retardation syndromes and autosomal recessive primary microcephaly (MPCH) in human patients ([@bib59]; [@bib7]).

The initiation of centriole duplication requires a conserved set of five core proteins: PLK4 (ZYG-1 in *C. elegans*), CEP192 (SPD-2 in *C. elegans* and Spd-2 in *Drosophila*), CPAP (also known as CENPJ, SAS-4 in *C.elegans* and Sas-4 in *Drosophila*), STIL (SAS-5 in *C. elegans* and Ana-2 in *Drosophila*) and SAS6 ([@bib46]; [@bib47]; [@bib15]; [@bib16]; [@bib36]; [@bib61]; [@bib64]; [@bib40]). Of these components, PLK4 has been identified as the central regulator of centriole assembly ([@bib29]; [@bib3]). In mammalian cells, PLK4 is recruited to the centriole during G1 phase through binding to its centriole receptors CEP152 and CEP192, which encircle the proximal end of the parent centriole ([@bib10]; [@bib30]; [@bib38]; [@bib63]; [@bib71]). At G1-S phase transition, PLK4 transforms from a ring-like localization to a single focus on the wall of the parent centriole that marks the site of procentriole formation ([@bib38]; [@bib62]; [@bib70]; [@bib19]). This transition bears features of a symmetry breaking reaction and can be recreated in silico using two positive feedback loops that act on PLK4 ([@bib25]; [@bib45]). Binding of PLK4 to its centriole substrate STIL promotes activation of the kinase and is required for its ring-to-dot transformation ([@bib62]; [@bib56]; [@bib54]). PLK4 phosphorylates STIL in a conserved STAN motif to promote the binding and recruitment of SAS6 ([@bib62]; [@bib56]; [@bib18]; [@bib44]). SAS6 homo-oligomerizes to organize the central cartwheel, a stack of ring-like assemblies with nine-fold symmetry that provides the structural foundation for the procentriole ([@bib41]; [@bib75]; [@bib76]; [@bib13]; [@bib27]).

Following cartwheel assembly, the centriole protein CPAP plays a critical role in the formation and stabilization of the triplet microtubule blades that make up the procentriole wall. CPAP interacts with multiple centriole proteins including STIL ([@bib12]; [@bib73]; [@bib77]), CEP152 ([@bib10]; [@bib17]), CEP120 ([@bib51]), CEP135 ([@bib52]), and Centrobin ([@bib26]). The C-terminal TCP domain of CPAP directly binds to a highly conserved PRP motif in STIL ([@bib12]; [@bib73]; [@bib77]), while the N-terminal domain of CPAP interacts with α/β-tubulin heterodimers ([@bib69]; [@bib81]; [@bib33]). These interactions allow CPAP to act as a molecular link between the cartwheel and the triplet microtubule blades of the centriole wall. Importantly, an MCPH mutation in the CPAP TCP domain weakens the STIL-CPAP interaction, highlighting the importance of this complex in centriole assembly and function ([@bib12]; [@bib73]; [@bib5]). CPAP positively regulates centriolar microtubule growth and, consequently, overexpression of CPAP leads to the formation of overly long centrioles in human cells ([@bib72]; [@bib67]; [@bib43]). In addition to its role in controlling microtubule growth, CPAP also functions in recruiting PCM, either through the direct tethering of PCM proteins or by recruiting Plk1/Polo which is critical in promoting PCM assembly ([@bib80]; [@bib24]; [@bib9]; [@bib60]).

At present, the binding of SAS6 to the STAN motif of STIL is the only interaction known to be controlled by PLK4 kinase activity. While the regulation of this assembly step is conserved in humans and flies ([@bib62]; [@bib56]; [@bib18]; [@bib44]), it is unclear whether this takes place in *C. elegans*, where ZYG-1/PLK4 directly binds and recruits SAS6 to promote cartwheel assembly ([@bib48]). Moreover, although phosphomimetic mutations in the crucial PLK4 phosphorylation sites in the STAN motif of STIL are functional, they cannot support centriole duplication in the absence of PLK4 kinase activity ([@bib39]). This suggests that PLK4 must phosphorylate STIL, or other substrates, at additional sites to promote centriole assembly. Indeed, recent work in *Drosophila* identified additional PLK4 phosphorylation sites required for centriole biogenesis in the N-terminus of Ana2/STIL, but exactly how these phosphorylation events contribute to centriole formation remains unclear ([@bib19]; [@bib55]).

In this manuscript, we identify a conserved PLK4 phosphorylation site on STIL that promotes binding to CPAP in vitro and in vivo. This phospho-dependent binding interaction is conserved in flies and allows STIL to link the growing cartwheel to the outer microtubule wall of the centriole. Together, our findings offer insight into a novel step in centriole assembly that is regulated by PLK4 kinase activity.

Results {#s2}
=======

PLK4 phosphorylates STIL to promote CPAP binding {#s2-1}
------------------------------------------------

PLK4 phosphorylates conserved residues in the STIL STAN motif to promote binding to SAS6 ([@bib62]; [@bib56]; [@bib18]). To determine whether phosphorylation of STIL by PLK4 might affect the interaction of STIL with other components of the centriole duplication machinery, we tested the ability of Myc-GFP-STIL to interact with its known centriolar binding partners in the presence of kinase active (PLK4^WT^) or kinase dead (PLK4^KD^) PLK4. Active PLK4 triggers its own degradation and thus, we used a PLK4^∆24^ mutant that stabilizes the active kinase by preventing PLK4-induced autodestruction ([@bib32]). Expression of kinase active PLK4^∆24^-mCherry increased the binding of STIL to SAS6 in cells ([Figure 1A](#fig1){ref-type="fig"}), but did not increase binding to the STIL-interacting partners RTTN ([@bib8]) or CEP85 ([Figure 1B,C](#fig1){ref-type="fig"}) ([@bib53]). Unexpectedly, we observed that PLK4 kinase activity promoted a robust increase in STIL binding to CPAP, suggesting that PLK4 kinase activity also controls the interaction of CPAP with STIL ([Figure 1D](#fig1){ref-type="fig"}).

![PLK4 kinase activity promotes STIL binding to CPAP.\
(**A--D**) HEK293FT cells were transfected with the indicated constructs, subjected to co-immunoprecipitation and immunoblotted with the indicated antibodies. PLK4 activity increased binding of both SAS6 and CPAP to STIL.](elife-46054-fig1){#fig1}

To determine how PLK4 phosphorylation promotes binding of CPAP to STIL, we mapped in vitro PLK4 phosphorylation sites on STIL using mass spectrometry. Recombinant full-length GST-STIL was phosphorylated with the His-PLK4 kinase domain in vitro. Of the 84 in vitro phosphorylation sites we identified on STIL, S428 was of particular interest as it is highly conserved, matches the PLK4 consensus phosphorylation sequence and is positioned close to the known CPAP binding region on STIL ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) ([@bib12]; [@bib37]; [@bib35]; [@bib31]). To determine if phosphorylation of STIL S428 was responsible for enhancing the binding of CPAP to STIL, we co-expressed FLAG-CPAP and a wild type (WT) or S428A mutant of Myc-GFP-STIL in the presence of kinase active or inactive PLK4^∆24^-mCherry. The expression of kinase active PLK4 promoted a \> 7 fold increase in the amount of CPAP bound to WT STIL, but this increased binding was not observed with STIL S428A ([Figure 2B](#fig2){ref-type="fig"}). To test if this phospho-regulated binding interaction can be reconstituted with purified components, we performed GST-pull down experiments on recombinant WT or S428A GST-STIL that had been phosphorylated with the His-PLK4 kinase domain and then incubated with a recombinant Flag-CPAP TCP domain. Phosphorylation of WT GST-STIL with PLK4 increased binding to the Flag-TCP domain by \~2.5 fold, but this increased binding was not observed with STIL S428A ([Figure 2C](#fig2){ref-type="fig"}). The use of the CPAP TCP domain rather than full-length protein may explain the more modest increase in CPAP binding to STIL in vitro compared to in vivo. These data show that phosphorylation of STIL S428 promotes CPAP binding to STIL in vitro and in vivo.

![Phosphorylation of STIL by PLK4 promotes increased CPAP binding.\
(**A**) Schematic of full-length STIL showing locations of the known CPAP binding motif, coiled-coil (CC), and STAN motif important for SAS6 binding. Sequence alignment shows the conserved CPAP binding motif. The fragment of STIL crystalized with CPAP is shown by the gray bar ([@bib12]). STIL residues key to the STIL-CPAP interaction (P404, R405, and P408) are highlighted. The conserved PRxxPxP motif is indicated in red. Alignment was generated using Muscle under standard parameters. (**B**) HEK293FT cells were transfected with the indicated constructs, subjected to co-immunoprecipitation and immunoblotted with the indicated antibodies. The graph represents the mean of relative levels of immunoprecipitated Flag/Myc signal across three independent experiments. A dot displays measurements from each experiment. Error bars represent the standard error of the mean. (**C**) Recombinant full-length GST-STIL (WT or S428A) was bound to beads, phosphorylated by recombinant 6xHis-PLK4 kinase domain, and then incubated with Flag-CPAP TCP domain. GST-pulldowns were analyzed by immunoblotting with the indicated antibodies. The graph represents the mean of relative levels of Flag-TCP pulled down with GST-STIL. A dot displays measurements from each experiment. Error bars represent the standard error of the mean. (**D**) Recombinant full-length GST-STIL (WT or S428A) was phosphorylated in vitro by recombinant 6xHis-PLK4 kinase domain. Samples were immunoblotted with the indicated antibodies. PLK4 phosphorylates STIL at multiple sites leading to a reduced mobility on an SDS-PAGE gel. CBB represents 'coomassie brilliant blue' staining and shows the recombinant PLK4 kinase domain. (**E**) HEK293FT cells were transfected with the indicated constructs and immunoblotted with the indicated antibodies. (**F**) *Drosophila melanogaster* S2 cells were transfected with the indicated constructs, subjected to co-immunoprecipitation and immunoblotted with the indicated antibodies. *Dm*PLK4^SBM^ ([S]{.ul}limb [B]{.ul}inding [M]{.ul}utant) is stabilized through mutation of critical serines in the Slimb-binding domain to alanine, which prevents auto-regulation of the kinase ([@bib65]). The graph represents the mean of relative levels of immunoprecipitated Flag/Myc signal across three independent experiments. A dot displays measurements from each experiment. Error bars represent the standard error of the mean. Asterisks indicate statistically significant differences between measurements (\*: p\<0.05; \*\*: p\<0.005; \*\*\*: p\<0.0005). Statistics for all figures were calculated using a one-sample t-test where mean values were tested as being different from a value of 100.\
10.7554/eLife.46054.006Figure 2---source data 1.[Figure 2](#fig2){ref-type="fig"} Data and Statistical Analysis.](elife-46054-fig2){#fig2}

To demonstrate STIL S428 is a *bona fide* PLK4 phosphorylation site, we raised a phospho-specific antibody to this site. The affinity-purified pS428 antibody recognized recombinant GST-STIL in the presence of ATP and the His-PLK4 kinase domain, but not in the absence of ATP ([Figure 2D](#fig2){ref-type="fig"}). Moreover, recognition of phosphorylated GST-STIL by the pS428 antibody was abolished by the S428A mutation, demonstrating the specificity of the pS428 antibody ([Figure 2D](#fig2){ref-type="fig"}). To determine if PLK4 can phosphorylate STIL S428 in cells, we co-expressed WT or a S428A mutant of Myc-GFP-STIL with kinase active or inactive PLK4^∆24^-mCherry ([Figure 2E](#fig2){ref-type="fig"}). The pS428 antibody recognized WT STIL in the presence of kinase active, but not kinase inactive, PLK4, showing that PLK4 phosphorylates STIL at S428 in vitro and in vivo.

The phosphorylation-dependent binding of CPAP to STIL is conserved in flies {#s2-2}
---------------------------------------------------------------------------

*D. melanogaster* PLK4 (DmPLK4) was recently shown to phosphorylate the STIL homolog Ana2 at S38, a residue equivalent to S428 in the human STIL ([@bib19]; [@bib55]) ([Figure 2A](#fig2){ref-type="fig"}). Phosphorylation of S38 was shown to be required for Ana2 recruitment ([@bib19]) but was reported to not alter Ana2 binding to the CPAP orthologue DmSas4 ([@bib55]). We reasoned that this discrepancy might arise because PLK4 is a low-abundance protein that is activated at the centriole and is unable to efficiently phosphorylate a significant fraction of the transfected Ana2. To test this possibility, we transfected *D. melanogaster* S2 cells with either WT or S38A Myc-GFP-Ana2 and Flag-DmSas4 in the presence or absence of a stabilized version of *Dm*PLK4^SBM^-mCherry ([@bib65]). *Dm*PLK4^SBM^ promoted a \> 6 fold increase in the amount of *Dm*Sas4 bound to WT Ana2, but this increased binding was not observed with Ana2 S38A ([Figure 2F](#fig2){ref-type="fig"}). These data suggest that the increased binding of CPAP/*Dm*Sas4 to phosphorylated STIL/Ana2 is conserved between human and flies.

PLK4 phosphorylates STIL S428 to promote centriole duplication {#s2-3}
--------------------------------------------------------------

To test the requirement of STIL S428 phosphorylation by PLK4 for centriole biogenesis, we integrated doxycycline-inducible, siRNA-resistant, WT or S428A Myc-GFP-STIL transgenes a pre-defined genomic locus in a DLD-1 host cell line. As a control, we also generated DLD-1 cells expressing a Myc-GFP-STIL S1116A transgene, which contains a mutation at a conserved PLK4 phosphorylation site in the STIL STAN motif required for efficient binding to SAS6 ([@bib62]; [@bib56]; [@bib18]). WT, S1116A and S428A Myc-GFP-STIL transgenes were all expressed to similar levels in cells ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}), and at a level \~2--3 fold higher than endogenous STIL. Depletion of STIL by siRNA for 48 hours resulted in 100% of mitotic cells with ≤2 centrioles, and this effect was almost completely rescued by expression of the WT STIL transgene ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}) without promoting substantial centriole overduplication. By contrast, expression of either STIL S428A or S1116A only led to a partial rescue of centriole duplication (61% S428A cells and 70% S1116A cells contain ≤2 centrioles in mitosis) ([Figure 3A](#fig3){ref-type="fig"}). Importantly, preventing S428 phosphorylation did not affect the ability of STIL to bind to or stimulate PLK4 kinase activity, suggesting that a failure to activate PLK4 kinase activity is not responsible for the failure of centriole duplication ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}) ([@bib56]). These data show that phosphorylation of STIL S428 by PLK4 promotes centriole duplication.

![STIL S428 phosphorylation promotes centriole duplication.\
(**A**) Quantification showing the number of mitotic Centrin foci in cells that were depleted of endogenous STIL and induced to express a siRNA-resistant Myc-GFP-STIL transgene as indicated. Error bars represent the standard error of the mean across three independent experiments. Representative images show example mitotic cells. Scale bars represent 5 µm. (**B**) The table shows abbreviations for Myc-GFP-STIL transgenes with multiple mutations. 'PRP' represents a triple mutation of P404A, R405A, and P408A. (**C**) Quantification of the relative centrosomal levels of Myc-GFP-STIL constructs from (**A**) in S/G2 phase cells with at least 40 cells measured per experiment. Bars represent the mean of at least three independent experiments with the average within each experiment shown as a dot. Error bars represent the standard error of the mean. (**D**) Representative images of data shown in (**C**). Scale bar represents 5 µm. (**E**) HEK293FT cells were transfected with the indicated constructs and subjected to co-immunoprecipitation and immunoblotted with the indicated antibodies. Graph represents the mean of relative levels of immunoprecipitated Flag/Myc signal across three independent experiments. A dot displays measurement from each experiment. Error bars represent the standard error of the mean. Asterisks indicate statistically significant differences between measurements (\*: p\<0.05; \*\*: p\<0.005; \*\*\*: p\<0.0005; \*\*\*\*: p\<0.0001). For [Figure 3A](#fig3){ref-type="fig"}, statistics were calculated using an unpaired t-test against the fraction of cells containing less than four centrioles in mitosis. For [Figure 3C and E](#fig3){ref-type="fig"}, statistics were calculated using a one-sample t-test where mean values were tested as being different from a value of 100.\
10.7554/eLife.46054.012Figure 3---source data 1.[Figure 3](#fig3){ref-type="fig"} Data and Statistical Analysis.\
10.7554/eLife.46054.013Figure 3---source data 2.[Figure 3---figure supplement 4](#fig3s4){ref-type="fig"} Data and Statistical Analysis.](elife-46054-fig3){#fig3}

Preventing STIL S428 phosphorylation phenocopies mutations in the CPAP binding motif of STIL {#s2-4}
--------------------------------------------------------------------------------------------

CPAP interacts with STIL via a short proline-rich region containing a highly conserved PRxxPxP motif ([Figure 2A](#fig2){ref-type="fig"}) ([@bib12]). To test whether defective CPAP binding causes the failure to rescue centriole duplication with STIL S428A, we created a PRP mutant of STIL by mutating the conserved [PR]{.ul}PI[P]{.ul}SP CPAP binding motif to [AA]{.ul}PI[A]{.ul}SP (P404A, R405A, P408A). This mutation did not affect PLK4's ability to phosphorylate STIL on S428 ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). As expected, the STIL PRP mutant showed impaired binding to CPAP ([Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). Expression of Myc-GFP-STIL PRP led to only a partial rescue of centriole duplication in cells depleted of endogenous STIL by siRNA, similar to that of the STIL S428A mutation ([Figure 3A](#fig3){ref-type="fig"}). Combining the S428A or PRP mutation with the S1116A mutation in the STIL STAN motif that impairs binding to SAS6 prevented any rescue of centriole duplication ([Figure 3A,B](#fig3){ref-type="fig"}). By contrast, a Myc-GFP-STIL transgene containing both the S428A and PRP mutation rescued centriole duplication to a level similar to that observed with a STIL transgene that contained either mutation on its own ([Figure 3A,B](#fig3){ref-type="fig"}). Collectively, these data suggest that S428 phosphorylation and the PRxxPxP motif of STIL function in the same pathway to promote CPAP binding to STIL, and that they both are in a separate pathway from mutations that disrupt SAS6 binding to STIL.

To evaluate the impact of disrupting CPAP and SAS6 binding on the centriole targeting of STIL, we measured the levels of Myc-GFP-STIL transgenes at the centriole in S/G2 phase cells depleted of endogenous STIL. Preventing phosphorylation at S428 reduced the localization of Myc-GFP-STIL by 28%, compared to that of the WT transgene ([Figure 3C,D](#fig3){ref-type="fig"}). Preventing phosphorylation at S1116 in the STAN motif reduced the abundance of STIL at the centriole by \~2 fold, as previously reported ([Figure 3C](#fig3){ref-type="fig"}) ([@bib56]). However, preventing phosphorylation of both sites reduced the centriole localization of STIL by 80%, suggesting that stable incorporation of STIL into the centriole requires strong binding to both CPAP and SAS6 ([Figure 3B,C,D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Combining the S428A and PRP mutations did not diminish the levels of centriolar STIL below that observed with either mutation alone ([Figure 3C](#fig3){ref-type="fig"}). This provides further evidence that the S428A and PRP mutations function in the same pathway and act to reduce the stability of CPAP binding to STIL.

Phosphorylation of the STIL STAN motif by PLK4 does not require STIL S428 phosphorylation {#s2-5}
-----------------------------------------------------------------------------------------

Experiments in flies showed that *Dm*PLK4 phosphorylates S38 to promote Ana2 recruitment to the centriole and then phosphorylates conserved residues in the STAN motif to enable SAS6 recruitment ([@bib19]; [@bib55]). However, we found that phosphorylation of STIL S428 in human cells does not abolish the centriolar recruitment of STIL ([Figure 3C,D](#fig3){ref-type="fig"}). To determine whether phosphorylation of the STAN motif requires phosphorylation of STIL S428, or vice versa, we monitored phosphorylation of STIL S428 and S1116 using phospho-specific antibodies. Expression of kinase active PLK4^∆24^-mCherry promoted phosphorylation of a Myc-GFP-STIL transgene at both S428 and S1116, and mutation of either site did not prevent phosphorylation of the other ([Figure 3---figure supplement 4A](#fig3s4){ref-type="fig"}). To test if PLK4-mediated phosphorylation of the STIL STAN motif at the centriole requires phosphorylation of S428, we monitored phosphorylation of S1108 in the STAN motif using a phospho-specific antibody ([@bib56]). Although treatment with the PLK4 inhibitor centrinone abolished STIL S1108 phosphorylation, the S428A or PRP motif mutation did not affect phosphorylation of STIL S1108 ([Figure 3---figure supplement 4B](#fig3s4){ref-type="fig"}). These data show that phosphorylation of the STIL STAN motif by PLK4 does not require prior phosphorylation of STIL S428.

Stable centriole recruitment of STIL requires STIL S428 phosphorylation {#s2-6}
-----------------------------------------------------------------------

To examine how S428 phosphorylation affects the binding dynamics of centriolar STIL, we performed Fluorescence Recovery after Photobleaching (FRAP) in cells depleted of endogenous STIL and expressing Myc-GFP-STIL transgenes. Myc-GFP-STIL WT partially recovered following bleaching, showing that STIL exists in both mobile and immobile pool at the procentriole ([Figure 4A](#fig4){ref-type="fig"}, Myc-GFP-STIL WT, recovery percentage (R%)=38%). Consistent with previous observations, mutation of the S1116 phosphorylation site increased the mobile fraction of centriolar STIL ([Figure 4A](#fig4){ref-type="fig"}, Myc-GFP-STIL S1116A, R% = 71%) ([@bib56]). Importantly, the S428A and PRP mutants of STIL also showed an increased recovery of centriolar STIL ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}); Myc-GFP-STIL S428A, R% = 57%; Myc-GFP-STIL PRP, R% = 58%), suggesting that CPAP binding allows more stable incorporation of STIL into the procentriole.

![STIL S428 phosphorylation promotes the stable integration of CPAP into the centrosome.\
(**A**) Cells were depleted of endogenous STIL and replaced with the indicated transgene. Myc-GFP-STIL centrosomal foci were photobleached, and fluorescence recovery was measured. The number of quantified photobleaching and recovery events are indicated. Representative timepoints are shown below. Error bars represent the standard error of the mean. (**B**) Cells were depleted of endogenous STIL and CPAP and replaced with the indicated Myc-STIL-T2A-GFP-CPAP transgene. GFP-CPAP centrosomal foci were photobleached, and fluorescence recovery was measured. The number of quantified photobleaching events is indicated. Representative timepoints are shown below. Error bars represent the standard error of the mean. Asterisks indicate statistically significant differences between measurements (\*: p\<0.05; \*\*: p\<0.005; \*\*\*: p\<0.0005). Statistics were calculated using an unpaired t-test against the population of recovery measurements between indicated samples at the 340 s timepoint.\
10.7554/eLife.46054.017Figure 4---source data 1.[Figure 4](#fig4){ref-type="fig"} Data and Statistical Analysis.\
10.7554/eLife.46054.018Figure 4---source data 2.[Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} Data and Statistical Analysis.\
10.7554/eLife.46054.019Figure 4---source data 3.[Figure 4---figure supplement 2](#fig4s2){ref-type="fig"} Data and Statistical Analysis.](elife-46054-fig4){#fig4}

To understand how mutations in STIL affect centrosomal CPAP dynamics, we monitored centrosomal GFP-CPAP turnover using FRAP by knocking down endogenous CPAP and expressing a siRNA-resistant Myc-GFP-CPAP transgene.

As previously reported, Myc-GFP-CPAP partially recovered after photobleaching ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}), Myc-GFP-CPAP, R% = 51%) ([@bib42]). Surprisingly, performing the same measurements in cells depleted of STIL led to an almost complete turnover of Myc-GFP-CPAP ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}, Myc-GFP-CPAP, STIL siRNA, R% = 96%). While STIL is uniquely localized to the procentriole, CPAP is present at both the parent centriole and procentriole. In addition, CPAP has been reported to localize in the PCM material ([@bib70]), consistent with a proposed role in recruiting PCM proteins ([@bib80]; [@bib24]; [@bib9]; [@bib60]). Since we bleach all of the pools of CPAP in the FRAP experiments, we cannot distinguish which centrosomal populations of CPAP are dynamic and which are stably bound. Nevertheless, given STIL localizes exclusively to the procentriole, one interpretation of our data is that STIL is required for the stable incorporation of CPAP at the procentriole, while the parental centriole and PCM pool of CPAP are dynamic and display a more transient association with the centrosome.

To test the role of STIL S428 phosphorylation in modulating CPAP turnover at the centrosome, we integrated into DLD1 cells a Myc-STIL-T2A-GFP-CPAP transgene in which siRNA-resistant Myc-STIL and siRNA-resistant GFP-CPAP were both expressed from the same doxycycline-inducible promoter. As expected, Myc-STIL expression significantly suppressed the increased turnover of GFP-CPAP observed in cells depleted of endogenous CPAP and STIL ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}, GFP-CPAP, Myc-STIL WT background, R% = 50%). However, mutation of S428 or the PRP motif on STIL increased the turnover of GFP-CPAP compared with WT STIL ([Figure 4B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}, GFP-CPAP, Myc-STIL S428A background, R% = 69%; GFP-CPAP, Myc-STIL PRP background, R% = 67%). Expression of Myc-STIL S1116A did not increase GFP-CPAP turnover, indicating that the increase in GFP-CPAP turnover in a Myc-STIL S428A background reflects a specific defect in the STIL/CPAP interaction ([Figure 4B](#fig4){ref-type="fig"}, GFP-CPAP, Myc-STIL S1116A background, R% = 55%). These data suggest that STIL binding allows a more stable incorporation of CPAP into the centrosome, possibly by facilitating interactions with CPAP at the procentriole. However, since the depletion of STIL resulted in a higher level of CPAP turnover than specifically disrupting the STIL/CPAP interaction, it is likely STIL recruits additional proteins that collectively act to stabilize the incorporation of CPAP into the centrosome. Together, our data show that the interaction of CPAP with STIL allows both proteins to incorporate more stably into the centrosome.

Mutations in the CPAP TCP domain cause less stable CPAP incorporation into the centrosome {#s2-7}
-----------------------------------------------------------------------------------------

To better understand the requirement of the STIL/CPAP interaction in centriole duplication, we constructed an RNAi-replacement system in DLD-1 cells where endogenous CPAP was depleted by siRNA and replaced with near physiological levels (\~2--3 fold higher) of an siRNA-resistant Myc-GFP-CPAP transgene ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5B](#fig5){ref-type="fig"}). Knockdown of CPAP by siRNA resulted in 81% of mitotic cells with ≤2 centrioles, and this was largely rescued by expression of the CPAP WT transgene ([Figure 5C](#fig5){ref-type="fig"}) without promoting centriole overduplication. By contrast, expression of a CPAP transgene with mutations in the TCP domain that reduced binding to STIL (F1229A or E1235K), led to a partial rescue of centriole duplication (58% of F1229A cells and 48% of E1235K cells contain ≤2 centrioles in mitosis) ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5D](#fig5){ref-type="fig"}) ([@bib12]; [@bib31]). Importantly, the presence of these TCP domain mutations increased the turnover of Myc-GFP-CPAP at the centrosome ([Figure 5E](#fig5){ref-type="fig"}, Myc-GFP-CPAP R% = 51%; Myc-GFP-CPAP F1229A, R% = 76%; Myc-GFP-CPAP E1235K, R% = 67%), but did not alter the abundance of the Myc-GFP-CPAP or STIL at the centrosome ([Figure 5F--H](#fig5){ref-type="fig"}). Collectively, these data support the conclusion that the STIL-CPAP interaction facilitates the stable centrosomal integration of CPAP, but that this interaction does not have a major impact on the level to which CPAP accumulates at the centrosome.

![Mutations in the CPAP TCP domain cause less stable CPAP incorporation into the centrosome.\
(**A**) Experimental outline for the CPAP RNAi-replacement experiments. (**B**) Immunoblot showing the Myc-GFP-CPAP transgene expression levels after knockdown of endogenous CPAP. Note that a background band (denoted by a red asterisk) appears in control lanes that overlaps with the Myc-GFP-CPAP transgene. (**C**) Quantification showing the number of mitotic Centrin foci in cells depleted of endogenous CPAP and induced to express a siRNA-resistant Myc-GFP-CPAP transgene as indicated. Error bars represent the standard error of the mean across three independent experiments. (**D**) HEK293FT cells were transfected with the indicated constructs, subjected to co-immunoprecipitation and immunoblotted with the indicated antibodies. Graph represents the mean of relative levels of immunoprecipitated Flag/Myc signal across three independent experiments. A dot indicates the average within each experiment. Error bars represent the standard error of the mean. (**E**) Cells were depleted of endogenous CPAP and replaced with the indicated transgene. Myc-GFP-CPAP centrosomal foci were photobleached, and fluorescence recovery was measured. The number of quantified photobleaching and recovery events is indicated. Error bars represent the standard error of the mean. Representative timepoints are shown below. Note that 'WT' trace is repeated from [Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}. (**F**) Quantification of the relative centrosomal levels of Myc-GFP-CPAP from S/G2 phase cells with at least 40 cells measured per experiment. Bars represent the mean of at least three independent experiments with the average within each experiment shown as a dot. Error bars represent the standard error of the mean. (**G**) Quantification of the relative centrosomal levels of STIL from S/G2 phase cells with at least 40 cells measured per experiment. Bars represent the mean of at least three independent experiments with the average within each experiment shown as a dot. Error bars represent the standard error of the mean. (**H**) Representative images from data quantified in (**F**) and (**G**). Scale bar represents 5 µm. Asterisks indicate statistically significant differences between measurements (\*: p\<0.05; \*\*: p\<0.005; \*\*\*: p\<0.0005). For [Figure 5C](#fig5){ref-type="fig"}, statistics were calculated using an unpaired t-test against the fraction of cells containing less than four centrioles in mitosis. For [Figure 5D,F and G](#fig5){ref-type="fig"}, statistics were calculated using a one-sample t-test where mean values were tested as being different from a value of 100. For [Figure 5E](#fig5){ref-type="fig"}, statistics were calculated using an unpaired t-test against the population of recovery measurements between indicated samples at the 340 s timepoint.\
10.7554/eLife.46054.022Figure 5---source data 1.[Figure 5](#fig5){ref-type="fig"} Data and Statistical Analysis.\
10.7554/eLife.46054.023Figure 5---source data 2.[Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} Data and Statistical Analysis.](elife-46054-fig5){#fig5}

STIL depletion reduces the localization of CPAP to the centrosome {#s2-8}
-----------------------------------------------------------------

To further test whether the overall level of CPAP present at the centrosome depends on STIL, we measured centrosomal CPAP levels in S/G2 cells depleted of STIL by siRNA. STIL knockdown reduced the level of CPAP at the centrosome by \~30% ([Figure 5---figure supplement 1A--C](#fig5s1){ref-type="fig"}). Importantly, we observed that centrosomal CPAP levels were similar following depletion of endogenous STIL and expression of a WT or mutant Myc-GFP-STIL transgene ([Figure 5---figure supplement 1D,E](#fig5s1){ref-type="fig"}). This suggests a model in which CPAP is localized to the parent centriole independently of STIL, while procentriole localized CPAP requires STIL for stable binding. However, our data argue that the role of STIL in recruiting CPAP to the centrosome is largely independent of the STIL/CPAP interaction and likely depends on the recruitment of other proteins. This is supported by our FRAP analysis which showed that depletion of STIL increased the turnover of CPAP at the centriole from 51% to 96%, while disruption of STIL binding to CPAP increased CPAP turnover to only \~70%. We conclude that the recruitment of the majority of CPAP present at the centrosome does not require CPAP binding to STIL.

Recruitment of CPAP to de novo formed centrioles requires STIL S428 phosphorylation {#s2-9}
-----------------------------------------------------------------------------------

The multiple populations of CPAP present at the centrosome prevented us from specifically testing the requirement of STIL S428 phosphorylation for CPAP recruitment to the procentriole. To analyze the role of STIL S428 phosphorylation in recruiting CPAP specifically to assembling procentrioles, we induced the formation of freestanding de novo centrioles in cells expressing various STIL mutants. DLD-1 cells expressing a Myc-GFP-STIL transgene were chronically treated with the PLK4 inhibitor centrinone to remove centrioles ([@bib79]). Acentriolar cell lines were then depleted of endogenous STIL using siRNA for twenty-four hours, and centrinone was removed to induce the formation of freestanding de novo centrioles ([Figure 6A](#fig6){ref-type="fig"}). De novo centrioles were defined as foci marked by both PLK4 and Centrin ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). As expected, depletion of STIL suppressed de novo centriole assembly, and this was rescued by expression of a WT Myc-GFP-STIL transgene (48% and 87% of cells expressing WT STIL contained de novo centrioles at 24 and 72 hr after centrinone washout, respectively) ([Figure 6B](#fig6){ref-type="fig"}). Acentriolar cell lines expressing a S428A, S1116A, or PRP Myc-GFP-STIL transgene were all deficient in assembling de novo centrioles, with only 25%, 12%, and 33% of cells containing PLK4 and Centrin positive foci at 72 hr after centrinone removal, respectively. While cells expressing S1116A Myc-GFP-STIL formed very few GFP-STIL/PLK4 foci, the number of foci observed in cells expressing S428A and PRP Myc-GFP-STIL was comparable to that observed with the WT STIL transgene ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). This suggests that cells expressing the S428A and PRP mutant STIL fail centriole assembly at a later stage than those expressing the S1116A mutant of STIL.

![STIL S428 phosphorylation is required for recruitment of CPAP to de novo centrioles.\
(**A**) Experimental outline for de novo centriole assembly assay. DLD-1 cells were maintained in 500 nM centrinone for seven or more days to deplete centrioles, and then endogenous STIL was knocked down with siRNA. Twenty-four hours later, centrinone was washed out, and the expression of a siRNA-resistant Myc-GFP-STIL transgene was induced with doxycycline. Cells were analyzed at 24, 48, and 72 hr post-centrinone washout. (**B**) Quantification showing the number of Centrin foci in interphase cells under the indicated conditions. Bars represent the mean of three independent experiments in which at least 40 cells were counted per condition. Error bars represent the standard error of the mean. 'Post-wo' refers to post-washout. A Centrin focus was counted as a de novo centriole if it overlapped with a PLK4 focus (see [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). (**C**) Quantification showing the number of Myc-GFP-STIL foci, or endogenous STIL foci in parental line, in cells under the indicated conditions. 'Post-wo' refers to post-washout. Bars represent the mean of three independent experiments in which at least 40 cells were counted per condition. Error bars represent the standard error of the mean. (**D**) Representative images of de novo centriole formation showing CPAP localization. Cells were fixed at 24 hr post-centrinone washout. Scale bar represents 5 µm. (**E**) Representative images of de novo centriole formation showing SAS6 localization. Cells were fixed at 24 hr post-centrinone washout. Scale bar represents 5 µm. (**F--H**) Quantification of the relative localization of (**F**) Myc-GFP-STIL, (**G**) CPAP, and (**H**) SAS6 at de novo centrioles at 24 hr post-centrinone washout. Bars represent the mean of three independent experiments in which at least 40 cells were quantified per mutant, and a dot indicates the average within each experiment. Error bars represent the standard error of the mean. Asterisks indicate statistically significant differences between measurements (\*: p\<0.05; \*\*: p\<0.005; \*\*\*: p\<0.0005; \*\*\*\*: p\<0.0001). For [Figure 6B and C](#fig6){ref-type="fig"}, statistics were calculated using an unpaired t-test against the fraction of cells containing no Centrin foci or GFP-STIL foci, respectively, after 72 hr post-washout. For [Figure 6F,G and H](#fig6){ref-type="fig"}, statistics were calculated using a one-sample t-test where mean values were tested as being different from a value of 100.\
10.7554/eLife.46054.026Figure 6---source data 1.[Figure 6](#fig6){ref-type="fig"} Data and Statistical Analysis.](elife-46054-fig6){#fig6}

To determine why the S428A and PRP mutations fail de novo centriole formation after forming STIL/PLK4 foci, we measured the recruitment of SAS6 and CPAP to the newly formed GFP-STIL/PLK4 foci. WT Myc-GFP-STIL recruited both CPAP and SAS6 to as expected ([Figure 6D--H](#fig6){ref-type="fig"}). While recruitment of SAS6 was identical in WT, S428A, and PRP Myc-GFP-STIL, the S428A and PRP mutations resulted in a \> 90% reduction in the amount of CPAP recruitment to the GFP-STIL/PLK4 foci ([Figure 6D--H](#fig6){ref-type="fig"}). Together, these data suggest that S428A and PRP mutant STIL bind to SAS6 and assemble a cartwheel but fail to recruit CPAP to complete the formation of de novo centrioles.

Discussion {#s3}
==========

Significant progress has been made in understanding the composition of centrioles and how protein interactions can direct centriole assembly ([@bib1]; [@bib34]; [@bib20]; [@bib21]; [@bib28]). However, we have a limited understanding of which assembly steps are controlled by PLK4 to maintain the number of centrioles in cycling cells. Our data now establish that PLK4 phosphorylates its centriole substrate STIL on a conserved site close to the PRP motif to promote STIL binding to CPAP in vitro and in vivo. The STIL/CPAP complex is only the second binding interaction shown to be controlled by PLK4 and highlights a new regulated step in centriole assembly.

Our data lead us to propose a model whereby active PLK4 phosphorylates STIL at the site of procentriole assembly in two different regions with distinct functional consequences ([Figure 7](#fig7){ref-type="fig"}): phosphorylation of multiple residues in the STAN motif, most notably S1116, allows STIL binding to SAS6 to promote cartwheel assembly. Second, phosphorylation of S428 promotes the binding of the STIL PRP motif to CPAP, thereby linking the growing cartwheel to the triplet microtubules of the centriole wall. This model is consistent with our analysis of de novo centriole assembly, which showed that phosphorylation of the STIL STAN motif is required to recruit SAS6 to the site of procentriole assembly while phosphorylation of STIL S428 is required at a later stage to recruit CPAP to the cartwheel. Moreover, super-resolution imaging of *Drosophila* centrioles has revealed that the C-terminal region of Ana2/STIL containing the STAN motif is located closer to the cartwheel hub, while the N-terminal region containing the PRP motif is positioned close to the C-terminus of Sas-4/CPAP at the periphery of the cartwheel ([@bib22]). A mutation in the CPAP TCP domain that causes microcephaly in humans has been shown to decrease the affinity of CPAP to STIL ([@bib12]; [@bib73]; [@bib5]). Also, mutations in STIL that reside in the CPAP and SAS6 interacting motifs have also been identified in patients with microcephaly, although the significance of these alterations remains to be determined ([@bib14]).

![Model depicting the early stages of de novo centriole formation.\
A PLK4 focus forms and phosphorylates STIL at S1116 in the STAN motif to recruit SAS6 and initiate cartwheel assembly. Phosphorylation of STIL at S428 by PLK4 promotes CPAP binding and connects the growing cartwheel to the triplet microtubules of the centriole wall. In the absence of STIL S428 phosphorylation, STIL is able to recruit SAS6 and promote cartwheel assembly. However, STIL S428A fails to recruit CPAP and link the cartwheel to the microtubule wall, leading to a failure of de novo centriole assembly. In the absence of STIL S1116 phosphorylation, STIL is not effectively recruited to a PLK4 focus and cartwheel assembly fails.](elife-46054-fig7){#fig7}

Although recruitment of CPAP to assembling de novo centrioles requires STIL S428 phosphorylation, this modification is not required for recruiting the bulk of CPAP to the centrosome. We envisage two possible explanations for this discrepancy. First, although sharing obvious similarities, de novo centriole assembly may have some distinct requirements compared with canonical centriole biogenesis. For example, the presence of a parent centriole may help direct CPAP recruitment to the site of procentriole assembly; CPAP localized in the PCM could be recruited to the procentriole by some of CPAP's other interacting partners in the absence of STIL S428 phosphorylation. A second possibility is that multiple pools of CPAP at the centrosome (parent centriole, procentriole and PCM associated) may obscure the ability to accurately monitor the role of STIL phosphorylation in CPAP recruitment at the nascent procentriole. In any case, it is clear that even if the STIL-CPAP interaction is not strictly necessary for the recruitment of either protein to canonically duplicating centrioles, it does allow for the more stable integration of these proteins into the centrosome.

A previous study solved the structure of the CPAP TCP domain bound to a short STIL peptide (residues 395--416) containing the PRP motif but lacking the S428 phosphorylation site ([@bib12]). A central question that now emerges is how phosphorylation of S428, which is positioned \~20 amino acids downstream of the core PRP interaction motif in STIL, promotes binding to CPAP in cells. We envisage two, non-mutually exclusive possibilities. First, phosphorylation creates an extended binding interface that increases the affinity of STIL to CPAP. Indeed, sequence conservation in the CPAP TCP domain is not confined to the region that directly interacts with the PRP motif of STIL, but extends further along the surface of the TCP domain beta sheet, suggesting that additional contacts with STIL may occur in this region ([@bib12]). Moreover, there is high conservation around the S428 phosphorylation site on STIL, and this conserved motif was proposed to be well positioned to form an extended interaction interface with conserved residues in the CPAP TCP domain ([@bib12]). Phosphorylation of STIL S428 could, therefore, seed the binding of this conserved region and cooperatively enhance the binding of STIL to CPAP.

An alternative hypothesis is that S428 phosphorylation generates a conformational change that unmasks the PRP motif in STIL and exposes it for binding to CPAP. In support of this model, work in *Drosophila* has shown that phosphorylation of the homologous site (S38) on Ana2/STIL leads to a dramatic mobility shift in an SDS page gel that is likely to reflect a significant conformational change in Ana2 ([@bib19]). It is notable that *C. elegans* SAS-5/STIL lacks an obvious PRP motif, but directly binds to SAS-4/CPAP through a disordered region ([@bib12]). Moreover, the SAS-4/CPAP TCP domain is required for the incorporation of SAS-4 into the centriole in *C. elegans*. SAS-5 has also been shown to bind to microtubules through a region that overlaps with the SAS-4 binding domain, suggesting that the interaction of SAS-5 with microtubules and SAS-4 may be mutually exclusive ([@bib4]). In the future, it will be interesting to investigate if ZYG-1/PLK4 kinase activity regulates the critical SAS-5/SAS-4 interaction in *C. elegans* by switching SAS-5 from binding microtubules to an association with SAS-4.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\             Designation                                   Source or\                             Identifiers          Additional\
  (species) or\                                                           reference                                                   information
  resource                                                                                                                            
  ------------------------- --------------------------------------------- -------------------------------------- -------------------- --------------------------------------------------------------------------------------------------------------------
  Cell line (*H. sapien*)   DLD-1 LacZeo                                  [@bib56]. DOI: 10.1083/jcb.201502088                        available upon request

  Cell line (*H. sapien*)   DLD-1 LacZeo;\                                [@bib56]. DOI: 10.1083/jcb.201502088                        available upon request
                            Myc-GFP-STIL WT                                                                                           

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-GFP-STIL S1116A             [@bib56]. DOI: 10.1083/jcb.201502088                        available upon request

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-GFP-STIL S428A              this study                                                  DLD-1 cell line in which a Myc-GFP-STIL construct with indicated mutation is integrated at a single locus

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-GFP-STIL PRP                this study                                                  DLD-1 cell line in which a Myc-GFP-STIL construct with indicated mutation is integrated at a single locus

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-GFP-STIL PRP/28A            this study                                                  DLD-1 cell line in which a Myc-GFP-STIL construct with indicated mutation is integrated at a single locus

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-GFP-STIL 28A/16A            this study                                                  DLD-1 cell line in which a Myc-GFP-STIL construct with indicated mutation is integrated at a single locus

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-GFP-STIL PRP/16A            this study                                                  DLD-1 cell line in which a Myc-GFP-STIL construct with indicated mutation is integrated at a single locus

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-GFP-STIL\                   this study                                                  DLD-1 cell line in which a Myc-GFP-STIL construct with indicated mutation is integrated at a single locus
                            PRP/28A/16A                                                                                               

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-GFP-CPAP WT                 this study                                                  DLD-1 cell line in which a Myc-GFP-CPAP construct with indicated mutation is integrated at a single locus

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-GFP-CPAP F1229A             this study                                                  DLD-1 cell line in which a Myc-GFP-CPAP construct with indicated mutation is integrated at a single locus

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-GFP-CPAP E1235K             this study                                                  DLD-1 cell line in which a Myc-GFP-CPAP construct with indicated mutation is integrated at a single locus

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-STIL-T2A-GFP-CPAP           this study                                                  DLD-1 cell line in which a Myc-STIL-T2A-GFP-CPAP construct with indicated mutation is integrated at a single locus

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-STIL S428A -T2A-GFP-CPAP    this study                                                  DLD-1 cell line in which a Myc-STIL-T2A-GFP-CPAP construct with indicated mutation is integrated at a single locus

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-STIL PRP -T2A-GFP-CPAP      this study                                                  DLD-1 cell line in which a Myc-STIL-T2A-GFP-CPAP construct with indicated mutation is integrated at a single locus

  Cell line (*H. sapien*)   DLD-1 LacZeo; Myc-STIL S1116A -T2A-GFP-CPAP   this study                                                  DLD-1 cell line in which a Myc-STIL-T2A-GFP-CPAP construct with indicated mutation is integrated at a single locus

  Antibody                  Mouse monoclonal, Myc                         EMD Millipore                          Cat. No. 05--724     (WB) use 1:1000

  Antibody                  Mouse monoclonal, Flag                        Sigma                                  Cat. No. F1804       (WB) use 1:1000

  Antibody                  Rabbit polyclonal, mCherry                    gift from Joo Soek-Han                                      (WB) use 1:1000

  Antibody                  Rabbit polyclonal, STIL (WB)                  Bethyl                                 Cat. No. A302-441A   (WB) use 1:2500

  Antibody                  Rabbit polyclonal, STIL pS428                 this study                                                  see Materials and methods. (WB) use 1:1000

  Antibody                  Rabbit polyclonal, STIL pS1116                [@bib56]. DOI: 10.1083/jcb.201502088                        (WB) use 1:1000

  Antibody                  Rabbit polyclonal, STIL pS1108                [@bib56]. DOI: 10.1083/jcb.201502088                        (IF) use 1:250

  Antibody                  Mouse monoclonal, tubulin                     Sigma                                  Cat. No. T6199       (WB) use 1:1000

  Antibody                  Rabbit polyclonal, Plk4 pT170                 this study                                                  see Materials and methods. (WB) use 1:1000

  Antibody                  Goat polyclonal, CEP192                       this study                                                  see Materials and methods. (IF) use 1:1000

  Antibody                  Rabbit polyclonal, Centrin                    this study                                                  see Materials and methods. (IF) use 1:1000 in

  Antibody                  Rabbit polyclonal, CPAP                       gift from Karen Oegema                                      (WB or IF) use 1:1000

  Antibody                  Rabbit polyclonal, STIL (IF)                  [@bib56]. DOI: 10.1083/jcb.201502088                        (IF) use 1:250

  Antibody                  Rabbit polyclonal, Plk4                       [@bib56]. DOI: 10.1083/jcb.201502088                        (IF) use 1:1000

  Antibody                  Mouse monoclonal, SAS6                        Santa Cruz                             Cat. No. sc-81431    (IF) use 1:200

  Chemical compound, drug   centrinone                                    Tocris Bioscience                      Cat. No. 5687        use at 500 nM
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Antibody production {#s4-1}
-------------------

Human Centrin2 (a.a. 1--172) was cloned into a pET-23b bacterial expression vector (Novagen) containing an N-terminal 6xHis-SUMO1 tag. Recombinant protein was purified from *E. coli* using Ni--NTA beads (BioRad), cleaved from beads with SUMO protease and used for immunization in rabbits (ProSci). An N-terminal CEP192 fragment (a.a. 1--211) was cloned into a pGEX GST bacterial expression vector containing an N-terminal GST tag. Recombinant protein was purified from *E. coli* using glutathione sepharose beads (GoldBio), cleaved from beads with PreScission protease (GE) and used for immunization in goats. Rabbit and goat immune sera were affinity-purified using standard procedures. Affinity-purified antibodies were directly conjugated to Alexa Fluor 488, DyLight 550, or DyLight 647 fluorophores (Thermo Scientific) for use in immunofluorescence.

A synthetic phospho-peptide based on the human STIL sequence flanking serine 428 \[CSVPEL(pS)LVDG\] was synthesized, coupled to KLH and injected into rabbits (ProSci). Polyclonal pS428 antibodies were affinity-purified using the hSTIL phosphopeptide coupled to a SulfoLink Coupling Resin (Thermo Scientific). Additionally, a synthetic phospho-peptide based on the human PLK4 sequence flanking threonine 170 \[HEKHY(pT)LCGTC\] was synthesized, coupled to KLH and injected into rabbits (ProSci). Polyclonal pT170 antibodies were affinity-purified using the human PLK4 phosphopeptide coupled to a SulfoLink Coupling Resin (Thermo Scientific).

Cell culture and drug treatments {#s4-2}
--------------------------------

Mammalian cell culture was performed as previously described ([@bib56]). Cells were maintained at 37°C in a 5% CO~2~ atmosphere with 21% oxygen. Cells were grown in Dulbecco\'s Modified Eagle Medium (DMEM) containing 10% FB Essence serum (VWR), 100 U/mL penicillin, 100 U/mL streptomycin and 2 mM L-glutamine. HEK293FT cells were used in co-transfection experiments, while Flp-In TRex-DLD-1 cells (a kind gift from Stephen Taylor, the University of Manchester, UK) were used in all other experiments. Flp-In TRex-DLD-1 cells were engineered using the Flp-In TRex Core Kit (Life Technologies) to stably express the Tetracycline repressor protein and contain a single, genomic FRT/*lac*Zeo site. Centrinone (a kind gift from Karen Oegema) was dissolved in DMSO and used at a final concentration of 500 nM. DLD-1 cell lines were authenticated using STR genotyping. All cell lines were determined to be free from mycoplasma contamination using DAPI staining.

Drosophila S2 cell culture and transfection {#s4-3}
-------------------------------------------

Drosophila S2 cells (a kind gift from Ji Hoon Kim) were cultured at room temperature in vented T-25 flasks with Schnedier media (Gibco) containing 10% Fetal Bovine Serum (Sigma). 1.5 × 10^6^ cells were seeded in a 6-well plate in 2 mL media. The following day cells were transfected with the indicated constructs using Effectene (QIAGEN) according to the manufacturer's protocol. Cells were harvested 48 hr later and subjected to co-immunoprecipitation (procedure below).

Cloning {#s4-4}
-------

Molecular cloning was performed as previously described ([@bib56]). All constructs were cloned into a pcDNA5/FRT/TO vector backbone (Life Technologies) and expressed from a CMV promoter. DNA constructs for Drosophila S2 transfection were cloned into a pAc vector backbone (Invitrogen).

Generation of stable cell lines and siRNA treatment {#s4-5}
---------------------------------------------------

Stable cell lines and siRNA treatment was performed as previously described ([@bib56]). Stable, isogenic cell lines expressing indicated constructs from a CMV promoter under the control of two Tetracycline operator sites were generated according to the manufacturer's recommendation using the FRT/Flp-mediated recombination in Flp-In TRex-DLD-1 cells (Life Technologies Flp-In TRex Core Kit). Expression of Myc-GFP-STIL was induced with 1 µg/mL Tetracycline (Sigma). Expression of Myc-GFP-CPAP was induced with 2 ng/mL Tetracycline. Expression of Myc-STIL-T2A-GFP-CPAP constructs was induced with 1 µg/mL Tetracycline. For RNA interference, 2 × 10^5^ cells were seeded in a 6-well plate, and duplexed siRNAs were introduced using RNAiMAX (Life Technologies) 24 hr later. siRNA directed against STIL (5'-GCUCCAAACAGUUUCUGCUGGAAU-3') or CPAP (5'-AGAAUUAGCUCGAAUAGAAUU-3') was purchased from Dharmacon, and control siRNA (Universal Negative Control \#1) was purchased from Sigma. 24 hr after transfection, Tetracycline was added to induce expression of RNAi-resistant Myc-GFP-STIL or Myc-STIL-T2A-GFP-CPAP. Expression of the Myc-GFP-CPAP transgene was induced concurrently with siRNA treatment. Cells were harvested and processed for immunoblotting or fixed for immunofluorescence 24 hr later.

De novo centriole formation assay {#s4-6}
---------------------------------

Acentriolar Flp-In TRex-DLD-1 cell lines were generated by culturing lines in centrinone at 500 nM for seven or more days. Cells were subjected to the siRNA protocol (above). 24 hr later, centrinone was washed out where noted by replacing media twice on cells for ten minutes each and then resuspending cells across multiple coverslips and adding Tetracycline at given concentrations depending on the cell line (concentrations above). Cells were fixed at 24, 48, and 72 hr post-washout as described below.

Co-immunoprecipitation {#s4-7}
----------------------

Co-immunoprecipitation was performed as previously described ([@bib56]). 2 × 10^6^ 293 FT cells were seeded into 10 cm^2^ dishes and 24 hr later were transfected with 3 µg of plasmid DNA. 48 hr later, transfected cells were lysed in lysis buffer \[10 mM Tris pH 7.5, 0.1% Triton X-100, 250 mM NaCl, 1 mM EDTA, 50 mM NaF, 50 mM β-glycerophosphate, 1 mM DTT, 500 nM microcystin, 1 mM PMSF and EDTA-free protease inhibitor tablet (Roche)\], sonicated and soluble extracts prepared. The supernatant was incubated with beads coupled to GFP-binding protein ([@bib66]). Beads were washed three times in lysis buffer, and immunopurified protein was analyzed by immunoblot.

Immunoblotting and immunofluorescence {#s4-8}
-------------------------------------

Immunoblotting and immunofluorescence were performed as previously described ([@bib56]). For immunoblot analysis, protein samples were separated by SDS-PAGE, transferred onto nitrocellulose membranes with a Trans-Blot Turbo Transfer System (BioRad) and probed with the following antibodies: tubulin (mouse DM1A anti-α-tubulin, Sigma, T6199, 1:5000), STIL (rabbit, Bethyl, A302-441A, 1:2500), FLAG M2 (mouse, Sigma, F1804, 1:1000), CPAP (rabbit, a kind gift from Karen Oegema, 1:1000), HA (rat, 3F10, Roche, 1:1000), Myc 4A6 (mouse, EMD Millipore, 1:1000), SAS6 (mouse, Santa Cruz, sc-81431, 1:1000), Plk4 pT170 (rabbit, this study, 1:1000) ([@bib57]), Plk4 (rabbit, this study, 1:3200), mCherry (rabbit, a kind gift from Joo Soek-Han, 1:1000), STIL pS1116 (([@bib56]), 1:500) and STIL pS428 (rabbit, this study, 1:1000). Blots were blocked with 3% BSA in PBST and washed with PBST. Phospho-antibody blots were blocked in TBS Starting Block (Thermo) supplemented with 0.05% Tween 20 and washed in TBST. Antibodies were diluted in respective blocking buffers.

For immunofluorescence, cells were grown on 18 mm glass coverslips and fixed in 100%--20C methanol for 10 min. Cells were blocked in 2.5% FBS, 200 mM glycine, and 0.1% Triton X-100 in PBS for 1 hr. Antibody incubations were conducted in the blocking solution for 1 hr. DNA was detected using DAPI, and cells were mounted in Prolong Antifade (Invitrogen). Staining was performed with the following primary antibodies: Centrin (rabbit, directly-conjugated, this study, 1:1000), Plk4 (rabbit, directly-labeled, [@bib56], 1:1000), STIL (rabbit, directly-conjugated, [@bib56], 1:250), STIL pS1108 (rabbit, [@bib56], 1:250), SAS6 (mouse, sc-81--431 Santa Cruz, 1:1000), CEP192 (goat, directly-labeled, this study, 1:000), CPAP-Cy3 (directly-labeled rabbit, a kind gift from Karen Oegema, Ludwig Institute for Cancer Research, CA,1:1000) and CENP-F (sheep, raised against CENP-F a.a. 1363--1640, a kind gift from Stephen Taylor, the University of Manchester, UK,1:1000). Secondary donkey antibodies were conjugated to Alexa Fluor 488, 555 or 650 (Life Technologies).

Immunofluorescence images were collected using a Deltavision Elite system (GE Healthcare) controlling a Scientific CMOS camera (pco.edge 5.5). Acquisition parameters were controlled by SoftWoRx suite (GE Healthcare). Images were collected at room temperature using an Olympus 60 × 1.42 NA or Olympus 100 × 1.4 NA oil objective at 0.2 μM z-sections and subsequently deconvolved in SoftWoRx suite. Images were acquired using Applied Precision immersion oil (N = 1.516). For quantification of signal intensity at the centrosome, deconvolved 2D maximum intensity projections were saved as 16-bit TIFF images. Signal intensity was determined using ImageJ by drawing a circular region of interest (ROI) around the centriole (ROI S). A larger concentric circle (ROI L) was drawn around ROI S. ROI S and L were transferred to the channel of interest, and the signal in ROI S was calculated using the following formula: IS -- \[(IL-IS/AL-AS) x AS\]

A = Area, I = Integrated pixel intensity.

Fluorescence recovery after photobleaching {#s4-9}
------------------------------------------

Fluorescence recovery after photobleaching was performed as previously described ([@bib56]). Cells were seeded into 4-chamber, 35 mm glass bottom culture dishes (Greiner) and maintained in cell culture medium at 37°C and 5% CO~2~ in an environmental control station. Images were collected using a Zeiss 40 × 1.4 NA PlanApochromat oil-immersion objective on a Zeiss LSM 780 confocal equipped with a solid-state 488 nm laser and a spectral GaAsP detector. Images were acquired using Carl Zeiss immersion oil (N = 1.518). Acquisition parameters, shutters, and focus were controlled by Zen black software (Zeiss). 11 × 0.5 µM z-sections were acquired for EGFP at each time point. Two consecutive pre-bleach scans were collected at 5% of the maximum ATOF value. Centrosome localized Myc-EGFP-STIL or EGFP-CPAP was bleached within a circular region encompassing the centrosome (\~3 µM in diameter) at 100% laser power with 100 µsec dwell time. Post-bleach scans were performed at 20 s time intervals for a total period of 400 s. Maximum intensity projections were created using Zen black. The integrated intensity value within a circular region of interest in the cytosol of the cell was subtracted from an identically sized region of interest drawn around the bleached centrosome. Recovery values were plotted relative to the difference between the fluorescence pre- and post-bleach.

Recombinant protein expression and purification {#s4-10}
-----------------------------------------------

Recombinant protein expression and purification was performed as previously described ([@bib56]). GFP-binding protein (GBP), His-hPlk4 (a.a. 1--416), and GST-Flag-CPAP TCP domain (aa 1142--1338) were expressed and purified from *E. coli* \[strain Rosetta (DE3)\] using standard procedures. Recombinant GST-hSTIL was expressed and purified from SF9 insect cells (Invitrogen) using the Bac-to-Bac expression system (Invitrogen). Infected cell pellets were suspended in lysis buffer (10 mM PO4^3-^ pH 7.4, 137 mM NaCl, 2.7 mM KCl, 10% glycerol, 2 mM MgCl~2~, 5 mM DTT, 100 nM Microcystin, 1 mM Na~3~V0~4~, 250 U of Benzonaze nuclease (Sigma), 1 mM PMSF and EDTA-free protease inhibitor tablet (Roche)) and lysed by sonication. After centrifugation at 15,000 rpm for 30 min, the supernatant was supplemented with 110 mM KCl and 0.1% Triton X-100 and incubated with Glutathione Sepharose beads (GE Healthcare) for 4 hr at 4°C. Beads were washed extensively in wash buffer \[10 mM PO4^3-^ pH 7.4, 137 mM NaCl, 2.7 mM KCl, 10% glycerol, 5 mM DTT, 0.1% Triton X-100, 100 mM KCl, 1 mM PMSF and EDTA-free protease inhibitor tablet (Roche)\] and protein eluted in elution buffer (10 mM PO4^3-^ pH 7.4, 137 mM NaCl, 2.7 mM KCl, 10% glycerol, with 40 mM reduced glutathione and 5 mM DTT). Protein was dialyzed into a final buffer of 10 mM PO4^3-^ pH 7.4, 137 mM NaCl, 2.7 mM KCl, and 10% glycerol. When necessary, the GST tag was removed by overnight incubation with GST-PreScission protease (GE Healthcare).

In vitro kinase assay {#s4-11}
---------------------

In vitro kinase assays were performed as previously described ([@bib56]). Assays were conducted for 30 min at 30°C in 20 mM Tris pH 7.5, 25 mM KCl, 1 mM DTT, and in the presence of 10 mM MgCl~2~ and 100 µM ATP. 2 µg of substrate was incubated with 1 µg of His-hPlk4 (a.a. 1--416). Kinase reactions were stopped with sample buffer and analyzed by SDS-PAGE and western blotting.

In vitro binding assay {#s4-12}
----------------------

Recombinant GST-hSTIL was bound to GSH resin (GoldBio) for four hours at 4°C in PBS, 10% glycerol, and 1 mM DTT. Beads were washed twice in kinase buffer (see above) supplemented with 10% glycerol and incubated with 6xHis-hPlk4 (a.a. 1--416) in kinase buffer with or without 10 µM cold ATP at 33°C for two hours. Reactions were then spun down and washed twice with cold binding buffer (50 mM Na-HEPES pH 7.5, 400 mM NaCl, 2 mM MgCl~2~, 1 mM EGTA, 1 mM DTT, 0.15% Triton-X 100, 100 nM Microcystin (Calbiochem) and 0.5 mg/ml BSA) and spun in binding buffer at 4°C for 2 hr in the presence of recombinant Flag-CPAP TCP domain. Beads were washed three times in binding buffer without BSA, and then proteins were eluted in SDS sample buffer and immunoblotted.

Mass spectrometry {#s4-13}
-----------------

Mass spectrometry was performed as previously described ([@bib56]). In-solution protein digestion was carried out using 'Filter Assisted Sample Preparation' (FASP) method ([@bib78]). Data- dependent MS/MS analysis of peptides was carried out on the LTQ-Orbitrap Velos ([www.thermoscientific.com](http://www.thermoscientific.com)) interfaced with Eksigent 2D nanoflow liquid chromatography system ([www.eksigent.com](http://www.eksigent.com) system). Peptides were enriched on a 2 cm trap column (YMC gel ODS-A S-10µm), fractionated on a 75 µm x 15 cm column packed with 5 µm, 100 Å Magic AQ C18 material (Michrom Bioresources), and electrosprayed through a 15 µm emitter (PF3360-75-15-N-5, New Objective). Reversed-phase solvent gradient consisted of 0.1% formic acid with increasing levels of 0.1% formic acid, 90% acetonitrile over a period of 90 min. LTQ orbitrap Velos was set at 2.0 kV spray voltage, full MS survey scan range was set at 350--1800 m/z, data-dependent HCD MS/MS analysis set for top eight precursors with minimum signal of 2000. Other parameters include peptide isolation width of m/z 1.9; dynamic exclusion limit 30 s and normalized collision energy 35; precursor and the fragment ions resolutions were 30,000 and 15,000, respectively. Internal mass calibration was applied using lock mass ion m/z = 371.101230.

Mass spectrometry raw files were automatically processed through Proteome Discoverer 1.4 software. Raw MS and MS/MS data were isotopically resolved with deconvolution and deisotoping using Thermo Scientific Xtract and MS2-processor software in addition to default spectrum selector node. The data were searched in Refseq human entries using Mascot (v2.2.6, Matrix Sciences) search engine interfaced with different processing nodes of Proteome Discoverer 1.4. Mass tolerances on precursor and fragment masses were set to 15 ppm and 0.03 Da, respectively. Peptide validator node was used for identification confidence and 1% false discovery rate cutoff was used to filter the peptides. Phosphorylation site probability was analyzed using phosphoRS 3.0 node in Proteome discoverer software ([@bib74]).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"PLK4 promotes centriole duplication by phosphorylating STIL to link the procentriole cartwheel to the microtubule wall\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Anna Akhmanova as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Jordan W Raff (Reviewer \#1).

The reviewers have discussed the reviews with one another and I have drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript Moyer and Holland provide compelling evidence that PLK4 phosphorylates STIL to promote its interaction with CPAP and so to promote centriole assembly. Although a similar phosphorylation event has previously been characterised by the Glover and Rogers groups for the fly homologue of STIL (Ana2), the reviewers agreed that the consequences of this phosphorylation described here were of sufficient novelty and general interest to warrant publication in *eLife*. The reviewers raised a number of important concerns, however, that will need to be addressed prior to acceptance.

Essential revisions:

1\) The relative level of expression of all the proteins tested here should be compared to the endogenous levels of expression. This information was provided in some experiments, but not in others.

2\) The reasons for using the PLK4^∆24^ mutation, and for using a form of PLK4 lacking the Polo boxes (potentially altering substrate specificity) for the in vitro kinase assays need to be stated more clearly. It would also help to put the results in Supplementary file 1 into a fuller context by reporting how many of the identified phosphorylation sites match the PLK4 consensus, and how many serines and threonines were not phosphorylated (and how many of these are conserved and/or conform to the consensus).

3\) Statistical analysis of the data was inconsistent and was often lacking. This led to some confusion as to what you describe as \"significant\". In particular your statement that \"the phosphorylation of STIL S428 in human cells does not play a significant role in the centrioles recruitment of STIL\" seems too strong in light of the data shown in Figure 3C (although the lack of statistics make it difficult to be sure). Statistics should be applied to all the relevant data (and the methods used fully explained in each figure legend).

4\) You point out towards the end of the paper that STIL is present on only the procentriole, whereas CPAP is present on both the mother centriole and the procentriole. This is potentially important for the interpretation of some of the localisation and FRAP experiments and should be stated much earlier in the manuscript. This leads to some potential confusion. For example, you conclude that the recruitment of the majority of CPAP present at the centrosome does not require STIL. At a first glance, this might seem to overturn the conventional wisdom that STIL recruits CPAP to the assembling daughter centriole, when, in fact, your data is largely consistent with this possibility (see, for example, Figure 3F, where it seems that CPAP is localised at the older centriole normally, but is not recruited to the new centriole in the presence of the S428A mutation). Thus, your quantification of total centrosome fluorescence, rather than individual centriole fluorescence, may be somewhat misleading to readers not paying careful attention. It seems you believe that STIL is recruiting CPAP to the procentriole, but is not required to maintain CPAP at mother centrioles that have already formed (presumably prior to the depletion of STIL) -- but your thinking on this only becomes clear in the Discussion. These points need to be presented more clearly. We think it would be helpful if you can provide simple schematics that illustrate your interpretation of what is occurring in the localisation and FRAP studies where this is an issue. This may require some thought.

5\) The centrinone washout experiment is a good attempt to get at the requirement for STIL phosphorylation in a simplified system where new centrioles form free of a mother centriole. However, in the absence of EM evidence, we think you need to be more cautious about the nature of the various foci that are observed.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"PLK4 promotes centriole duplication by phosphorylating STIL to link the procentriole cartwheel to the microtubule wall\" for further consideration at *eLife*. We decided there was no need to go back to the original reviewers as we feel that there are only a small number of remaining issues that will need to be addressed prior to acceptance, outlined below:

1\) You now show the levels of expression relative to the endogenous proteins for all your transgenically expressed proteins, but we think it important to state in the main text that you estimate that these are over expressed by \~2-3 fold and your arguments as to why this is not a problem.

2\) You should state why the DmPLK4^SBM^ protein is stabilised and what SBM stands for.

10.7554/eLife.46054.031

Author response

> Essential revisions:
>
> 1\) The relative level of expression of all the proteins tested here should be compared to the endogenous levels of expression. This information was provided in some experiments, but not in others.

We thank the reviewers for pointing out this omission. The expression of the Myc-GFP-STIL transgenes are shown in Figure 3---figure supplement 1A, B and is \~ 2-3-fold above that of endogenous STIL. In addition, in Figure 5B we show that the expression of the Myc-GFP-CPAP transgene is \~2-3-fold above that of endogenous CPAP. Although both the Myc-GFP-STIL and Myc-GFP-CPAP transgenes are overexpressed, expression of either transgene efficiently rescued centriole duplication failure after depletion of the respective endogenous protein and resulted in minimal centriole overduplication (Figure 3A and 5C).

> 2\) The reasons for using the PLK4^∆24^ mutation, and for using a form of PLK4 lacking the Polo boxes (potentially altering substrate specificity) for the in vitro kinase assays need to be stated more clearly. It would also help to put the results in Supplementary file 1 into a fuller context by reporting how many of the identified phosphorylation sites match the PLK4 consensus, and how many serines and threonines were not phosphorylated (and how many of these are conserved and/or conform to the consensus).

PLK4 exists as an obligate homodimer that phosphorylates itself in trans to trigger its own degradation by the proteasome. Consequently, kinase active PLK4 is extremely unstable and difficult to express in cells. We therefore used a PLK4^∆24^ mutant that lacks the phosphorylation sites required for self-destruction. The PLK4^∆24^ mutant also accumulates to the same level independent of kinase activity, which avoids the complication of having different levels of expression for kinase active and inactive PLK4. We have added the following sentence to the text to clarify this point: "Active PLK4 triggers its own degradation and thus, we used a PLK4^∆24^ mutant that stabilizes the kinase by preventing PLK4-induced autodestruction."

As the reviewers correctly pointed out, the in vitro kinase assays and pull-down experiments were carried out with a His-PLK4 kinase domain and not full-length recombinant PLK4. The reason for this is technical. First, full-length PLK4 is difficult to express and purify recombinantly. While we have succeeded in doing this in the past, the full-length GST-PLK4 protein is low-yield and less active than the kinase domain alone. Second, we have only succeeded in expressing PLK4 with the large solubility tag GST and in the in vitro pull-down experiments GST was used to pull-down on STIL. It was therefore more convenient to use a different affinity tag for PLK4 in this assay and we already had recombinant His-PLK4 kinase domain at hand. Finally, kinases in vitro are considered to be relatively promiscuous and therefore these assays should be treated with caution. Our interpretation is only that PLK4 *can* phosphorylate the residues we identify on STIL, but we are careful not to propose that PLK4 phosphorylates all of these sites in vivo. We have added the following sentence to the Results section to make it clear that our in vitro kinase assay used the PLK4 kinase domain and not the full-length protein: "Recombinant full-length GST-STIL was phosphorylated with the His-PLK4 kinase domain in vitro." We also more clearly highlight that the sites we identified are considered in vitro phosphorylation sites. "Of the 84 in vitro phosphorylation sites we identified on STIL, S428 was of particular interest as it is highly conserved, matches the PLK4 consensus phosphorylation sequence and is positioned close to the known CPAP binding region on STIL..."

Finally, we have added information to Supplementary file 1 to clarify how many serine and threonine residues were not phosphorylated by His-PLK4 kinase domain and how many of these sites matched the PLK4 consensus.

> 3\) Statistical analysis of the data was inconsistent and was often lacking. This led to some confusion as to what you describe as \"significant\". In particular your statement that \"the phosphorylation of STIL S428 in human cells does not play a significant role in the centrioles recruitment of STIL\" seems too strong in light of the data shown in Figure 3C (although the lack of statistics make it difficult to be sure). Statistics should be applied to all the relevant data (and the methods used fully explained in each figure legend).

We apologize for the confusion. We have now added statistical analysis for all of the major comparisons we make in the study. The statistical methods used are described in the figure legends and in the source manuscript file labelled 'Statistics Summary'.

> 4\) You point out towards the end of the paper that STIL is present on only the procentriole, whereas CPAP is present on both the mother centriole and the procentriole. This is potentially important for the interpretation of some of the localisation and FRAP experiments and should be stated much earlier in the manuscript. This leads to some potential confusion. For example, you conclude that the recruitment of the majority of CPAP present at the centrosome does not require STIL. At a first glance, this might seem to overturn the conventional wisdom that STIL recruits CPAP to the assembling daughter centriole, when, in fact, your data is largely consistent with this possibility (see, for example, Figure 3F, where it seems that CPAP is localised at the older centriole normally, but is not recruited to the new centriole in the presence of the S428A mutation). Thus, your quantification of total centrosome fluorescence, rather than individual centriole fluorescence, may be somewhat misleading to readers not paying careful attention. It seems you believe that STIL is recruiting CPAP to the procentriole, but is not required to maintain CPAP at mother centrioles that have already formed (presumably prior to the depletion of STIL) -- but your thinking on this only becomes clear in the Discussion. These points need to be presented more clearly. We think it would be helpful if you can provide simple schematics that illustrate your interpretation of what is occurring in the localisation and FRAP studies where this is an issue. This may require some thought.

We agree that our presentation of these data was not optimal. We have now modified the text to more clearly present our interpretation of this data, while at the same time being careful to not to overinterpret our findings. We have also reordered the presentation of the results and added a more detailed discussion of these experiments immediately after the data is presented. In summary, our data suggests that the CPAP-STIL interaction is required for the stable incorporation of both proteins at the centrosome, but specifically disrupting this interaction doesn't have a major impact on the degree to which either protein accumulates at the centrosome. Nevertheless, depletion of STIL does significantly increase the turnover of CPAP and decreases CPAP localization to the centrosome. This suggests that STIL recruits additional proteins that collectively act to stabilize the incorporation of CPAP into the centrosome.

To clarify our interpretation, we have added the following discussion of the CPAP turnover data: "While STIL is uniquely localized to the procentriole, CPAP is present at both the parent centriole and procentriole. \[...\] Nevertheless, given STIL localizes exclusively to the procentriole, one interpretation of our data is that STIL is required for the stable incorporation of CPAP at the procentriole, while the parental centriole and PCM pool of CPAP are dynamic and display a transient association with the centrosome."

We also state, "These data suggest that STIL binding allows a more stable incorporation of CPAP into the centrosome, possibly by facilitating interactions with CPAP at the procentriole. However, since the depletion of STIL resulted in a higher level of CPAP turnover than specifically disrupting the STIL/CPAP interaction, it is likely that STIL recruits additional proteins that collectively act to stabilize the incorporation of CPAP into the centrosome."

Later in the Results, we state: "This suggests a model in which CPAP is localized to the parent centriole independently of STIL, while procentriole localized CPAP requires STIL for stable binding. \[...\] We conclude that the recruitment of the majority of CPAP present at the centrosome does not require CPAP binding to STIL."

Although the CPAP-STIL interaction is not required for the bulk of CPAP recruitment to the centrosome, our analysis of de novo formed centrioles shows that STIL binding to CPAP is required for the recruitment of CPAP to the site of de novo centriole formation. We present two possible explanations for this discrepancy in the Discussion: "Although recruitment of CPAP to assembling de novo centrioles requires STIL S428 phosphorylation, this modification is not required for recruiting the bulk of CPAP to the centrosome. \[...\] In any case, it is clear that even if the STIL-CPAP interaction is not strictly necessary for the recruitment of either protein to canonically duplicating centrioles, it does allow for the more stable integration of these proteins into the centrosome."

> 5\) The centrinone washout experiment is a good attempt to get at the requirement for STIL phosphorylation in a simplified system where new centrioles form free of a mother centriole. However, in the absence of EM evidence, we think you need to be more cautious about the nature of the various foci that are observed.

We agree that this is an important consideration. We considered carrying out EM to confirm that the various STIL foci we observed were centrioles (for WT STIL), or centriole cartwheels (for STIL S428A). However, after consulting with an expert in the EM field, we came to the conclusion that we would not be able to detect free-standing cartwheel structures formed with the STIL S428A mutant using EM. Identifying centriole cartwheels using EM is exceedingly challenging and requires the presence of an existing centriole to direct the search area. Since we do not have EM to support our claims that the STIL foci we are observing are bone fide centrioles or free-standing cartwheels, we modified the text to state the recruitment of proteins to "STIL foci" as opposed to sites of "de novo centriole assembly".

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> 1\) You now show the levels of expression relative to the endogenous proteins for all your transgenically expressed proteins, but we think it important to state in the main text that you estimate that these are over expressed by \~2-3 fold and your arguments as to why this is not a problem.

We thank you for your suggestion. We have added this information to the text.

> 2\) You should state why the DmPLK4^SBM^ protein is stabilised and what SBM stands for.

We thank you for your suggestion. We have added this information to the corresponding figure legend.
